Canada Markets closed
  • S&P/TSX

    20,101.38
    -389.63 (-1.90%)
     
  • S&P 500

    3,923.68
    -165.17 (-4.04%)
     
  • DOW

    31,490.07
    -1,164.52 (-3.57%)
     
  • CAD/USD

    0.7798
    +0.0039 (+0.4991%)
     
  • CRUDE OIL

    110.23
    +0.64 (+0.58%)
     
  • BTC-CAD

    37,395.00
    -1,157.04 (-3.00%)
     
  • CMC Crypto 200

    649.49
    -21.19 (-3.16%)
     
  • GOLD FUTURES

    1,814.70
    -1.20 (-0.07%)
     
  • RUSSELL 2000

    1,774.85
    -65.45 (-3.56%)
     
  • 10-Yr Bond

    2.8860
    -0.0820 (-2.76%)
     
  • NASDAQ futures

    11,913.00
    -22.50 (-0.19%)
     
  • VOLATILITY

    30.96
    +4.86 (+18.62%)
     
  • FTSE

    7,438.09
    -80.26 (-1.07%)
     
  • NIKKEI 225

    26,238.40
    -672.80 (-2.50%)
     
  • CAD/EUR

    0.7426
    +0.0013 (+0.18%)
     

Stocks in play: Cardiol Therapeutics Inc.

  • Oops!
    Something went wrong.
    Please try again later.
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Announced that the U.S. Food and Drug Administration (FDA) has provided clearance to proceed with the Company's Investigational New Drug (IND) application to commence a Phase II, multi-center, double-blind, randomized, placebo-controlled trial designed to study the safety and tolerability of CardiolRx™, as well as its impact on myocardial recovery in patients presenting with acute myocarditis. Cardiol Therapeutics Inc. shares T.CRDL are trading up $0.13 at $3.94.

Read:

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting